Pharmacovigilance study of amphotericin B for mucormycosis in post-COVID and non-COVID patients at a tertiary care hospital in Eastern India

BACKGROUND: Mucormycosis is a rare but serious fungal infection which has dramatically increased in post-COVID patients. There is a paucity of safety data on amphotericin B (amphoB) used for mucormycosis treatment. OBJECTIVES: The objective of this prospective, observational, active safety surveilla...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Suparna, Bhattacharjee, Manjari, Hazra, Avijit, Mukhopadhyay, Pradip, Ray, Biman Kanti, Chatterjee, Sayan, Dubey, Souvik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043824/
https://www.ncbi.nlm.nih.gov/pubmed/36722553
http://dx.doi.org/10.4103/ijp.ijp_474_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043824/
https://www.ncbi.nlm.nih.gov/pubmed/36722553
http://dx.doi.org/10.4103/ijp.ijp_474_22

Ejemplares similares